TMAO has been reported to trigger activated NLRP3 inflammatory corpuscles in a dose-dependent and time-dependent manner to induce vascular inflammation, endothelial dysfunction, and ROS production (Yue et al., 2017; Wu et al., 2020). This evidence concerns the gene NLRP3 and endothelial dysfunction.